A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

December 23, 2025

Study Completion Date

December 30, 2025

Conditions

Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG

TS-172 20~60 mg/day

oral administration of TS-172 20\~60 mg/day

DRUG

Placebo

oral administration of placebo

Trial Locations (1)

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06745531 - A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Biotech Hunter | Biotech Hunter